MAIA Biotechnology Advances Phase 3 Trial of Ateganosine for 3L NSCLC in $50B Market
MAIA Biotechnology’s ongoing Phase 3 trial of ateganosine targets third-line non-small cell lung cancer patients with no standard of care, leveraging FDA Fast Track designation for an interim and full analysis. The telomere-targeting agent addresses an underserved group of roughly 50,000 annual US patients in a $50 billion immunotherapy market.
1. Phase 3 Clinical Progress
MAIA is conducting a full-approval Phase 3 trial of ateganosine in third-line NSCLC, incorporating interim and final analyses with a strong projected probability of technical success based on its clinical design.
2. FDA Fast Track Pathway
The FDA Fast Track designation grants MAIA priority review status for ateganosine as a third-line NSCLC therapy, expediting regulatory interactions for patients lacking an established standard of care.
3. Novel Telomere-Targeting Mechanism
Ateganosine is the first direct telomere-targeting agent in clinical development, inducing telomerase-mediated DNA damage and activating both innate cGAS/STING and adaptive T-cell immune responses when sequenced with checkpoint inhibitors.
4. Market and Patient Opportunity
By focusing on an underserved third-line NSCLC population of approximately 50,000 annual US patients, MAIA aims to capture a share of the $50 billion global immunotherapy market and establish a new therapeutic category.